LP-935509是一种口服有效的、选择性、ATP竞争性的接头蛋白-2相关激酶1 (AAK1) 抑制剂,IC50为3.3 nM。该化合物具有镇痛活性,并在神经性疼痛和SARS-CoV-2研究中具有潜在应用价值。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | LP-935509 is an orally active, potent, selective, ATP-competitive, and brain-penetrating inhibitor of AAK1 with an IC50 value of 3.3 nM and a Ki value of 0.9 nM. LP-935509 is also a potent inhibitor of BIKE (IC50=14 nM) and a mild inhibitor of GAK (IC50=320 nM). LP-935509 has antinociceptive activity and can be used in neuropathic pain and SARS-CoV-2 studies.The IC50 value of LP-935509 for inhibition of μ2 protein phosphorylation is 2.8 ± 0.4 nM, and for inhibition of μ2 protein polypeptide phosphorylation is 3.3 ± 0.7 nM[1]. |
Animal study | The oral bioavailability of LP-935509 (i.v. (1 mg/kg) or oral (10 mg/kg), once) was 100% with a plasma half-life of 3.6 hours. At a dose of 60 mg/kg, administered as a single oral dose, LP-935509 significantly reduced pain behaviour in animals. At a dose of 30 mg/kg, it can reverse thermal hyperalgesia in the CCI model[1]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.52mL 0.50mL 0.25mL |
12.61mL 2.52mL 1.26mL |
25.22mL 5.04mL 2.52mL |
CAS号 | 1454555-29-3 |
分子式 | C20H24N6O3 |
分子量 | 396.443 |
别名 | |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,2-8°C |
溶解度 |
DMSO: 50 mg/mL(126.12 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |